𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer

✍ Scribed by Stephane Paul; Etienne Regulier; Yves Poitevin; Horst Hormann; Bruce R. Acres

Book ID
105966573
Publisher
Springer-Verlag
Year
2002
Tongue
English
Weight
547 KB
Volume
51
Category
Article
ISSN
0340-7004

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Globin gene transfer for the treatment o
Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell-based gene therapy
✍ Michel Sadelain πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 197 KB

## Abstract The prospect of treating blood disorders with genetically modified stem cells is highly promising. This therapeutic approach, however, raises a number of fundamental biological questions, spanning several research fields. Further investigation is required to better understand how to iso

Cell-based gene therapy for repair of cr
Cell-based gene therapy for repair of critical size defects in the rat fibula
✍ ZaWaunyka W. Lazard; Michael H. Heggeness; John A. Hipp; Corinne Sonnet; Angie S πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 1002 KB

More than a decade has passed since the first experiments using adenovirus-transduced cells expressing bone morphogenetic protein 2 were performed for the synthesis of bone. Since this time, the field of bone gene therapy has tackled many issues surrounding safety and efficacy of this type of strate

The novel and effective nonplatinum, non
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma : Potential for decreased toxicity and combination with biologic therapy
✍ Roy S. Herbst; Fadlo R. Khuri; Charles Lu; Diane D. Liu; Frank V. Fossella; Bonn πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 545 KB

## Abstract ## BACKGROUND Gemcitabine and vinorelbine are two of the most active third‐generation agents for the treatment of advanced nonsmall cell lung carcinoma (NSCLC). The authors conducted a formal Phase II trial to evaluate the efficacy of this combination in both untreated and previously t